The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 13, 2018
Filed:
May. 17, 2018
Applicants:
Biomimetix Jv, Llc, Englewood, CO (US);
National Jewish Health, Denver, CO (US);
Inventors:
James D. Crapo, Englewood, CO (US);
Rebecca Oberley Deegan, Omaha, NE (US);
Assignees:
BioMimetix JV, LLC, Englewood, CO (US);
National Jewish Health, Denver, CO (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/555 (2006.01); A01N 59/20 (2006.01); A01N 43/713 (2006.01); A01N 59/16 (2006.01); C09K 8/035 (2006.01); A61K 8/19 (2006.01); A61K 8/49 (2006.01); A01N 55/02 (2006.01); C09K 8/524 (2006.01); C02F 5/12 (2006.01); C11D 3/00 (2006.01); A61Q 11/00 (2006.01); A61K 45/06 (2006.01); A61K 8/58 (2006.01); C02F 103/42 (2006.01); C02F 1/30 (2006.01); C02F 1/32 (2006.01); C02F 1/50 (2006.01); C02F 103/02 (2006.01);
U.S. Cl.
CPC ...
A61K 31/555 (2013.01); A01N 55/02 (2013.01); A01N 59/16 (2013.01); A01N 59/20 (2013.01); A61K 8/19 (2013.01); A61K 8/494 (2013.01); A61K 8/58 (2013.01); A61K 45/06 (2013.01); A61Q 11/00 (2013.01); C02F 5/12 (2013.01); C09K 8/035 (2013.01); C09K 8/524 (2013.01); C11D 3/0078 (2013.01); A61K 2800/58 (2013.01); C02F 1/30 (2013.01); C02F 1/32 (2013.01); C02F 1/50 (2013.01); C02F 2103/026 (2013.01); C02F 2103/42 (2013.01); C02F 2303/04 (2013.01); C02F 2303/20 (2013.01); C02F 2305/04 (2013.01); C02F 2307/14 (2013.01);
Abstract
An active agent for use in a method of, or for use in the preparation of a medicament for, treating or inhibiting the development of erectile dysfunction and/or incontinence following pelvic radiation treatment in a subject in need thereof, comprising administering said subject an active agent in a treatment effective amount, is described. The active agent has the general structure of Formula I: or a pharmaceutically acceptable salt thereof.